Harness 100% of human genetics for drug discovery

Proprietary AI and multiomics resolve the non-coding genome by mapping distant regulatory and structural variants to their genes, pathways, cell types, and 3D contacts across the full genome.

Explore our platform

A spin-off from:

Published in:

Only 1 in 10 drugs makes it to market

Genomics-guided drugs are 2.6× more likely to reach approval, raising success rates from under 10% to around 20%.

Lucid's team has been at the forefront of non-coding and structural variant research, well before these regions gained wider recognition. We bring deep expertise in uncovering regulatory drivers that conventional pipelines miss.

All-in-one AI powered platform for variant detection, prioritization, interpretation and data sharing

100% Genome Coverage

Fast Large-Scale Cohort Analysis

87% Fewer False Positives

Complete Variant Detection

Full Multi-Omics Integration

Our Services

Target identification

Map non-coding and structural variants to genes, pathways, and 3D contacts to rank causal, tractable targets
Biomarker discovery

Turn genome and multiomics signals into assay-ready biomarkers for enrichment and endpoints
Patient stratification

Define responder groups and cut trial noise with genetically anchored signatures

What we offer

Comprehensive genome analysis

Our software analyses the whole genome on cohort, family or individual level tailored to your needs.

Variation detection and ranking

Through the detection, ranking, and prioritization of mutations, you are provided with a manageable list of suggested pathogenic mutations.

Cutting edge AI Technology

Detection

High-quality detection methods that decrease false-positive structural variants by 87%, including DEL, DUP, INS and INV.

Prioritization

Disease-agnostic AI tool ranks over 80% of known pathogenic variants in the top 10. On top of that, we created a disease-specific scoring system with over 90% accuracy, it ensures precise prioritization for more reliable research outcomes.